Skip to main content
OpenTrials
Completed

NCT Number: NCT00362817

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. Survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Brain Tumor Brain Diseases Brain Metastases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Disease Attributes Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Ohio State University

Columbus, Ohio, 43210, United States

About this study

Rationale: Surgery and radiation are often used as treatments for brain metastases, or tumors in the brain that originate from other parts of the body. It is currently unknown whether patient survival or time to progression would experience additional benefits through the addition of chemotherapy. Previous research does appear to suggest that a chemotherapy regimen may improve outcomes of patients with brain metastases previously treated with radiation. The current study further evaluates this research question by providing patients with recurrent or symptomatic residual brain metastases with carboplatin and temozolomide, two chemotherapy agents. Temozolomide has demonstrated clinical antitumor efficacy against malignant gliomas and has been tested with some efficacy against several other types of cancer. This drug appears to have less adverse effects compared to other commonly used cancer drugs. Recent research indicates that temozolomide also has some efficacy against brain metastases. In addition, previous research indicates carboplatin's lack of severe toxicity in patients with this disease.

Treatment: Study participants will be treated with carboplatin and temozolomide. Carboplatin will be administered through intravenous infusions. Temozolomide will be given through oral pills. Before these drugs are administered, study participants will undergo a pre-treatment evaluation with physical and neuropsychological examinations, neuro-imaging, laboratory tests, quality of life assessment, and other procedures. Carboplatin will be given for two consecutive days. Temozolomide will be taken by study participants daily for five consecutive days. Both of these treatment schedules will be repeated every 28 days. Several tests and exams will be given throughout the study to closely monitor patients. Study treatments will be discontinued due to disease growth or unacceptable adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically confirmed systemic cancer

Exclusion criteria

  • Pregnant
  • Known CNS meningeal involvement with cancer

Treatment and study plan

carboplatin

Drug

IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.

Other names: Paraplatin, CBDCA

Temozolomide

Drug

150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.

Other names: Temodar

Primary outcomes

  1. Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide

    Time frame: up to 1 year

    Response was evaluated by MRI Criteria (MacDonald Criteria). The MacDonald criteria for determining tumor progression is determined through assessing the increase in size of an enhancing tumor on consecutive MRI scans and clinical assessment. Complete response occurs when there is a disappearance of all enhancing tumor on consecutive MRI scans at least one month apart. Partial response occurs at a >50% reduction in size of enhancing tumor on consecutive MRI scans at least one month apart. Progressive disease occurs when there is a >25% increase in size of enhancing tumor on consecutive MRI scans. Stable disease occurs in all remaining situations.

Secondary outcomes

  1. Analyze Patients Time to Progression

    Time frame: up to 60 weeks

    Responses to treatment was determined by comparing new enhanced MRI scans with those obtained at the previous evaluation (i.e., 2 treatment cycles ago) or with the pre-IA chemotherapy baseline scan, if it is the first follow-up MRI scan during treatment.

    MRI is the neuro-imaging modality of choice, since it is more accurate than CT for small tumors, multiple tumors, and tumors in the posterior fossa.58 The methodology used (techniques and equipment) must be identical for all scans. Lesions should be measured as the largest diameter seen on scan and the largest diameter perpendicular to that dimension.

  2. Determine the Overall Survival of Patients

    Time frame: up to 64 weeks

    From the time of protocol initiation

  3. Determine the Cause of Death of Patients After Treatment

    Time frame: up to 1 year

    To determine the cause of death (i.e., CNS tumor versus systemic disease progression) in patients after treatment.

  4. The Incidence and Severity of Centeral Nervous System (CNS) Toxicities

    Time frame: up to 24 weeks

    To determine the incidence and severity of CNS toxicity in patients treated with intra-arterial carboplatin and oral temozolomide.

  5. Quality of Life Assessment

    Time frame: up to 2 years

    To determine the impact of treatment on quality of life.

Sponsors and collaborators

Lead sponsor

Ohio State University Comprehensive Cancer Center

Other

Registry information

Official study title

Phase I/II Multicenter Trial of Intra-Arterial Carboplatin and Oral Temozolomide for the Treatment of Recurrent and Symptomatic Residual Brain Metastases.

Important dates

Study start
2004
Primary completion
2008
Study completion
2008
First posted
Aug 10, 2006
Registry last updated
Jun 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.